Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

iGlarLixi

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

Healthcare setting

Clinical research in 2026: The trends shaping tomorrow

Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

Cuttsy + Cuttsy

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Kymera reports positive results in clinical trial for atopic dermatitis

KT-621 could become a first-in-class, once-a-day oral treatment

- PMLiVE

FDA launches TEMPO digital health pilot

Digital technologies can improve remote patient care for those with chronic diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links